In silico pharmacogenetics of warfarin metabolism
Authors:
- 5 May 2006
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 24 (5) , 531-536
Abstract
Pharmacogenetic approaches can be instrumental for predicting individual differences in response to a therapeutic intervention. Here we used a recently developed murine haplotype-based computational method to identify a genetic factor regulating the metabolism of warfarin, a commonly prescribed anticoagulant with a narrow therapeutic index and a large variation in individual dosing. After quantification of warfarin and nine of its metabolites in plasma from 13 inbred mouse strains, we correlated strain-specific differences in 7-hydroxywarfarin accumulation with genetic variation within a chromosomal region encoding cytochrome P450 2C (Cyp2c) enzymes. This computational prediction was experimentally confirmed by showing that the rate-limiting step in biotransformation of warfarin to its 7-hydroxylated metabolite was inhibited by tolbutamide, a Cyp2c isoform-specific substrate, and that this transformation was mediated by expressed recombinant Cyp2c29. We show that genetic variants responsible for interindividual pharmacokinetic differences in drug metabolism can be identified by computational genetic analysis in mice.Keywords
This publication has 29 references indexed in Scilit:
- Computational genetics: from mouse to human?Trends in Genetics, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- IDENTIFICATION OF GLUTATHIONE-DERIVED METABOLITES FROM AN IP RECEPTOR ANTAGONISTDrug Metabolism and Disposition, 2004
- In Silico Genetics: Identification of a Functional Element Regulating H2 - E α Gene ExpressionScience, 2004
- Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography–mass spectrometry after solid-phase extractionJournal of Chromatography B, 2004
- Pharmacogenetics of oral anticoagulantsPharmacogenetics, 2003
- Oxidative Hydrolysis of Scoparone by Cytochrome P450 CYP2C29 Reveals a Novel MetaboliteBiochemical and Biophysical Research Communications, 2001
- The use of heterologously expressed drug metabolizing enzymes— state of the art and prospects for the futurePharmacology & Therapeutics, 1999
- Human P450 metabolism of warfarinPharmacology & Therapeutics, 1997
- Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics, 1994